MEX:LABB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MEX:LABB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Genomma Lab Internacional SAB de CV MEX:LABB
Genomma Lab InternacionalB de CV MEX:LABB +0.46% 66 Net Cash per Share is MXN-10.51 as of Mar. 2026. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.69 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 261 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 383141.38% on this metric.
Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Genomma Lab InternacionalB de CV's Net Cash per Share for the quarter that ended in Mar. 2026 was MXN-10.51.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Net Cash per Share or its related term are showing as below:
Genomma Lab InternacionalB de CV (MEX:LABB) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
The historical data trend for Genomma Lab InternacionalB de CV's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Genomma Lab InternacionalB de CV Annual Data | |||||||||||||||||||||
| Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||||
| Net Cash per Share | Get a 7-Day Free Trial |
|
|
-10.21 | -10.32 | -10.19 | -9.99 | -9.87 | |||||||||||||
| Genomma Lab InternacionalB de CV Quarterly Data | ||||||||||||||||||||
| Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | |
| Net Cash per Share | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
-11.11 | -10.70 | -10.44 | -9.87 | -10.51 | ||
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Genomma Lab InternacionalB de CV's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
| Net Cash per Share (A: Dec. 2025 ) | |||||||
| = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
| = | (3073.169 | - | 12723.177 | - | 0) | / | 977.753 |
| = | -9.87 |
Genomma Lab InternacionalB de CV's Net Cash per Share for the quarter that ended in Mar. 2026 is calculated as
| Net Cash per Share (Q: Mar. 2026 ) | = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
| = | (2809.041 | - | 13085.323 | - | 0) | / | 977.753 |
| = | -10.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.20 is trading 14.1% below its estimated GF Value™ of MXN17.69. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.